Emerging drugs for atopic dermatitis

Bibliography

• Leung DYM, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004;113(5):651-7
   PubMed Web of Science ®Google Scholar
• Elias PM. Barrier-repair therapy for atopic dermatitis: corrective lipid biochemical therapy. Expert Rev Dermatol 2008;3:441-52
   Google Scholar
• Hoffjan S, Epplen JT. The genetics of atopic dermatitis: recent findings and future options. J Mol Med 2005;83:682-92
   PubMed Web of Science ®Google Scholar
• Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004;13(1):R43-55
   PubMed Web of Science ®Google Scholar
• Palmer CN, Irvine AD, Terron-kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441-6
   PubMed Web of Science ®Google Scholar
• Ong PY, Boguniewicz M. Atopic dermatitis. Prim Care Clin Office Pract 2008;35:105-17
   PubMed Web of Science ®Google Scholar
• Faught J, Bierl C, Barton B, et al. Stress in mothers of young children with eczema. Arch Dis Child 2007;92:683-6
   PubMed Web of Science ®Google Scholar
• Ong PY, Boguniewicz M. Atopic dermatitis and contact dermatitis in the emergency room. Clin Ped Emerg Med 2007;8:81-6
   Google Scholar
• Cheigh NH. Managing a common disorder in children: atopic dermatitis. J Pediatr Health Care 2003;17:84-8
   PubMedGoogle Scholar
• Ong PY, Leung DYM. Atopic dermatitis. seventh edititon. In: Grammer LC, Greenberger PA, editors. Patterson's allergic diseases. Lippincott Williams & Wilkins Philadelphia, USA; Chapter 29, 2009
   Google Scholar
• Eigenmann PA, Sicherer SH, Borkowski TA, et al. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998;101:E8
   PubMed Web of Science ®Google Scholar
• Leung DYM, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Ann Allergy Asthma Immunol 2004;93:S1-21
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Hanifin JM, Luger TA, et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003;49:1088-95
   PubMedGoogle Scholar
• Tatham A. Atopic dermatitis, cutaneous steroids and cataracts in children: two case reports. J Med Case Reports 2008;2:124
   Google Scholar
• Bewley A, Dermatology Working Group. Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids. Br J Dermatol 2008;158:917-20
   PubMed Web of Science ®Google Scholar
• Williams HC, Grindlay DJ. What's new in atopic eczema? An analysis of the clinical significance of systematic reviews on atopic eczema published in 2006 and 2007. Clin Exp Dermatol 2008;33:685-8
   PubMed Web of Science ®Google Scholar
• Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005;152:1282-9
   PubMed Web of Science ®Google Scholar
• Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007;157:954-9
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Heinzerling L, Bieber T, et al. Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. Dermatology 2007;215:325-30
   PubMed Web of Science ®Google Scholar
• Fleischer AB Jr. Black box warning for topical calcineurin inhibitors and the death of common sense. Dermatol Online J 2006;12:2
   PubMedGoogle Scholar
• Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998;102:637-44
   PubMed Web of Science ®Google Scholar
• Ben-Gashir MA, Seed PT, Hay RJ. Predictors of atopic dermatitis severity over time. J Am Acad Dermatol 2004;50:349-56
   PubMed Web of Science ®Google Scholar
• Bußmann C, Bieber T, Novak N. Systemic therapeutic options for severe atopic dermatitis. J Dtsch Dermatol Ges 2008 [Epub ahead of print]
   Google Scholar
• Schmitt J, Schakel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol 2007;87:100-11
   PubMed Web of Science ®Google Scholar
• Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed 2007;23:106-12
   PubMed Web of Science ®Google Scholar
• Devillers AC, Oranje AP. Efficacy and safety of ‘wet-wrap’ dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol 2006;154:579-85
   PubMed Web of Science ®Google Scholar
• Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 2007;204:253-8
   PubMed Web of Science ®Google Scholar
• Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002;3:673-80
   PubMed Web of Science ®Google Scholar
• Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-60
   PubMed Web of Science ®Google Scholar
• Ong PY. Is pattern-recognition receptor(s) for Staphylococcus aureus defective in atopic dermatitis? Dermatology 2006;212:19-22
   PubMed Web of Science ®Google Scholar
• Gutman AB, Kligman AM, Sciacca J, James WD. Soak and smear: a standard technique revisited. Arch Dermatol 2005;141:1556-9
   PubMed Web of Science ®Google Scholar
• Tofte SJ, Hanifin JM. Current management and therapy of atopic dermatitis. J Am Acad Dermatol 2001;44:S13-16
   PubMed Web of Science ®Google Scholar
• Loden M. The clinical benefit of moisturizers. J Eur Acad Dermatol Venereol 2005;19:672-88
   PubMed Web of Science ®Google Scholar
• Williams RE, Gibson AG, Aitchison TC, et al. Assessment of a contact-plate sampling technique and subsequent quantitative bacterial studies in atopic dermatitis. Br J Dermatol 1990;123:493-501
   PubMed Web of Science ®Google Scholar
• Leung DY, Harbeck R, Bina P, et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 1993;92:1374-80
   PubMed Web of Science ®Google Scholar
• Ong PY, Patel M, Ferdman RM, et al. Association of staphylococcal superantigen-specific immunoglobulin E with mild and moderate atopic dermatitis. J Pediatr 2008;153:803-6
   PubMed Web of Science ®Google Scholar
• Ong PY, Leung DYM. Role of Staphylococcus aureus in atopic dermatitis. Second Edition. In: Bieber T, Leung DYM, editors, Atopic dermatitis. Marcel Dekker Ltd; 2009
   Google Scholar
• Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999;135:1522-5
   PubMed Web of Science ®Google Scholar
• Rukwied R, Lischetzki G, McGlone F, et al. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br J Dermatol 2000;142:1114-20
   PubMed Web of Science ®Google Scholar
• Kelsay K. Management of sleep disturbance associated with atopic dermatitis. J Allergy Clin Immunol 2006;118:198-201
   PubMed Web of Science ®Google Scholar
• Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002;11:12-24
   PubMed Web of Science ®Google Scholar
• Ikoma A, Steinhoff M, Stander S, et al. The neurobiology of itch. Nat Rev Neurosci 2006;7:535-47
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Zeichner JA, Eichenfield LF, et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. J Pediatr 2008;152:854-9
   PubMed Web of Science ®Google Scholar
• Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol 2005;15:31-6
   PubMed Web of Science ®Google Scholar
• Abramovits W, Boguniewicz M, Adult Atopiclair Study Group. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 2006;5:236-44
   PubMedGoogle Scholar
• Abramovits W, Perlmutter A. MimyX cream. Skinmed 2006;5:29-30
   PubMedGoogle Scholar
• Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 2008;22:73-82
   PubMed Web of Science ®Google Scholar
• Amado A, Taylor JS, Murray DA, Reynolds JS. Contact dermatitis to pentylene glycol in a prescription cream for atopic dermatitis: case report. Arch Dermatol 2008;144:810-2
   PubMed Web of Science ®Google Scholar
• Sugarman J, Parish LJ (2008) A topical lipid-based barrier repair formulation (EpiCeram) cream is highly-effective monotherapy for moderate-to-severe pediatric atopic dermatitis. J Invest Dermatol 128(Suppl. 1):S54 [Abstract](personal communication with Dr. Peter Elias)
   Google Scholar
• Simpson EL, Berry T, Tofte S, et al. Epiceram for the treatment of mild to moderate atopic dermatitis – a pilot study [abstract # 462]. J Invest Dermatol 2008;128:S77
   Google Scholar
• Goldstein AM, Abramovits W. Ceramides and the stratum corneum: structure, function, and new methods to promote repair. Int J Dermatol 2003;42:256-9
   PubMed Web of Science ®Google Scholar
• Gauger A, Mempel M, Schekatz A, et al. Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema. Dermatology 2003;207:15-21
   PubMed Web of Science ®Google Scholar
• Gauger A, Fischer S, Mempel M, et al. Efficacy and functionality of silver-coated textiles in patients with atopic eczema. J Eur Acad Dermatol Venereol 2006;20:534-41
   PubMed Web of Science ®Google Scholar
• Ricci G, Patrizi A, Bendandi B, et al. Clinical effectiveness of a silk fabric in the treatment of atopic dermatitis. Br J Dermatol 2004;150:127-31
   PubMed Web of Science ®Google Scholar
• Ricci G, Patrizi A, Mandrioli P, et al. Evaluation of the antibacterial activity of a special silk textile in the treatment of atopic dermatitis. Dermatology 2006;213:224-7
   PubMed Web of Science ®Google Scholar
• Senti G, Steinmann LS, Fischer B, et al. Antimicrobial silk clothing in the treatment of atopic dermatitis proves comparable to topical corticosteroid treatment. Dermatology 2006;213:228-33
   PubMed Web of Science ®Google Scholar
• Koller DY, Halmerbauer G, Bock A, Engstler G. Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3-month trial. Pediatr Allergy Immunol 2007;18:335-8
   PubMed Web of Science ®Google Scholar
• Stinco G, Piccirillo F, Valent F. A randomized double-blind study to investigate the clinical efficacy of adding a non-migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology 2008;217:191-5
   PubMed Web of Science ®Google Scholar
• Available from: http://www.nucryst.com/documents/rd_9202004.pdf
   Google Scholar
• Available from: http://www.nucryst.com/archived_releases/pr_9202006.htm
   Google Scholar
• Wohlrab J, Jost G, Abeck D. Antiseptic efficacy of a low-dosed topical triclosan/chlorhexidine combination therapy in atopic dermatitis. Skin Pharmacol Physiol 2007;20:71-6
   PubMed Web of Science ®Google Scholar
• Nakamura H, Aoki M, Tamai K, et al. Prevention and regression of atopic dermatitis by ointment containing NF-κB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther 2002;9:1221-9
   PubMed Web of Science ®Google Scholar
• Dajee M, Muchamuel T, Schryver B, et al. Blockade of experimental atopic dermatitis via topical NF-kappaB decoy oligonucleotide. J Invest Dermatol 2006;126:1792-803
   PubMed Web of Science ®Google Scholar
• Butler JM, Chan SC, Stevens S, Hanifin JM. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol 1983;71:490-7
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 1995;105:S84-88
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996;107:51-6
   PubMed Web of Science ®Google Scholar
• Giffiths CE, Van Leent EJ, Gilbert M, Traulsen J; Cipamyflline study group. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol 2002;147:299-307
   PubMed Web of Science ®Google Scholar
• Harada D, Takada C, Nosaka Y, et al. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol 2008 [Epub ahead of print]
   Google Scholar
• Tomimori Y, Muto T, Fukami H, et al. Chymase participates in chronic dermatitis by inducing eosinophil infiltration. Lab Invest 2002;82:789-94
   PubMed Web of Science ®Google Scholar
• Mizutani H, Schechter N, Lazarus G, et al. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med 1991;174:821-5
   PubMed Web of Science ®Google Scholar
• Omoto Y, Tokime K, Yamanaka K, et al. Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment. J Immunol 2006;177:8315-9
   PubMed Web of Science ®Google Scholar
• Badertscher K, Bronnimann M, Karlen S, et al. Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Arch Dermatol 2005;296:503-6
   Web of Science ®Google Scholar
• Watanabe N, Tomimori Y, Saito K, et al. Chymase inhibitor improves dermatitis in NC/Nga mice. Int Arch Allergy Immunol 2002;128:229-34
   PubMed Web of Science ®Google Scholar
• Watanabe N, Tomimori Y, Terakawa M, et al. Oral administration of chymase inhibitor improves dermatitis in NC/Nga mice. J Invest Dermatol 2007;127:971-3
   PubMed Web of Science ®Google Scholar
• Kammeyer A, Eggelte TA, Overmars H, et al. Oxidative breakdown and conversion of urocanic acid isomers by hydroxyl radical generating systems. Biochim Biophys Acta 2001;1526:277-85
   PubMed Web of Science ®Google Scholar
• Kammeyer A, Garssen J, Sleijffers A, et al. Suppression of different phases of systemic contact hypersensitivity by urocanic acid oxidation products. Photochem Photobiol 2004;80:72-7
   PubMed Web of Science ®Google Scholar
• Yamashiki M, Nishimura A, Kosaka Y. Effects of methylcobalamin (vitamin B12) on in vitro cytokine production of peripheral blood mononuclear cells. J Clin Lab Immunol 1992;37:173-82
   PubMedGoogle Scholar
• Stucker M, Pieck C, Stoerb C, et al. Topical vitamin B12–a new therapeutic approach in atopic dermatitis-evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial. Br J Dermatol 2004;150:977-83
   PubMed Web of Science ®Google Scholar
• Jansen T, Romiti R, Kreuter A, Altmeyer P. Rosacea fulminans triggered by high-dose vitamins B6 and B12. J Eur Acad Dermatol Venereol 2001;15:484-5
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/medwatch/safety/2008/safety08.htm#Raptiva
   Google Scholar
• Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993;178:211-22
   PubMed Web of Science ®Google Scholar
• Simon D, Wittwer J, Kostylina G, et al. Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008;122:423-4
   PubMed Web of Science ®Google Scholar
• Moul DK, Routhouska SB, Robinson MR, Korman NJ. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008;58:984-9
   PubMed Web of Science ®Google Scholar
• Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-31
   PubMed Web of Science ®Google Scholar
• Groves RW, Wilbraham D, Fuller R, Longphre M. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema [abstract #320]. J Invest Dermatol 2007;127:S54
   Web of Science ®Google Scholar
• Simon D, Hosli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122-8
   PubMed Web of Science ®Google Scholar
• Sediva A, Kayserova J, Vernerova E, et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008;121:1515-6
   PubMed Web of Science ®Google Scholar
• Bussmann C, Bockenhoff A, Henke H, et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006;118:1292-8
   PubMed Web of Science ®Google Scholar
• Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996;347:15-8
   PubMed Web of Science ®Google Scholar
• Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006;61:202-5
   PubMed Web of Science ®Google Scholar
• Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007;37:1277-85
   PubMed Web of Science ®Google Scholar
• Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007;120:164-70
   PubMed Web of Science ®Google Scholar
• Watchter E, Dees C, Harkins J, et al. Topical rose bengal: pre-clinical evaluation of pharmacokinetics and safety. Lasers Surg Med 2003;32:101-10
   PubMed Web of Science ®Google Scholar
• Gueniche A, Hennino A, Goujon C, et al. Improvement of atopic dermatitis skin symptoms by Vitreoscilla filiformis bacterial extract. Eur J Dermatol 2006;16:380-4
   PubMed Web of Science ®Google Scholar
• Gueniche A, Knaudt B, Schuck E, et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 2008 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999;41:533-9
   PubMed Web of Science ®Google Scholar
• Bigliardi PL, Stammer H, Jost G, et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 2007;56:979-88
   PubMed Web of Science ®Google Scholar
• Hagermark O, Rajka G, Bergvist U. Experimental itch in human skin elicited by rat mast cell chymase. Acta Derm Venereol 1972;52:125-8
   PubMed Web of Science ®Google Scholar
• Terakawa M, Fujieda Y, Tomimori Y, et al. Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis. Eur J Pharmacol 2008 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006;24:1551-7
   PubMed Web of Science ®Google Scholar
• Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev 2008;(3):CD003871
   Google Scholar
• Ohshima Y, Yamada A, Hiraoka M, et al. Early sensitization to house dust mite is a major risk factor for subsequent development of bronchial asthma in Japanese infants with atopic dermatitis: results of a 4-year followup study. Ann Allergy Asthma Immunol 2002;89:265-70
   PubMed Web of Science ®Google Scholar
• McGrath JA. Second cite. Clin Exp Dermatol 2006;31:826-8
   PubMed Web of Science ®Google Scholar
• Jancin B. Filaggrin Plays Critical Role in Skin Barrier Health. Skin Allergy News 2008;39:46
   Google Scholar
• Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007;120:150-5
   PubMed Web of Science ®Google Scholar
• Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203:2271-9
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Lowes MA, Fuentes-duculan J, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008;181:7420-7
   PubMed Web of Science ®Google Scholar
• Hata TR, Kotol P, Jackson M, et al. Administration of oral vitamin D induces cathelicidin production in atopic individuals. J Allergy Clin Immunol 2008;122:829-31
   PubMed Web of Science ®Google Scholar
• Dahten A, Koch C, Ernst D, et al. Systemic PPARgamma ligation inhibits allergic immune response in the skin. J Invest Dermatol 2008;128:2211-8
   PubMed Web of Science ®Google Scholar
• Staumont-Salle D, Abboud G, Brenuchon C, et al. Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 2008;121:962-8
   PubMed Web of Science ®Google Scholar
• Behshad R, Cooper KD, Korman NJ. A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch Dermatol 2008;144:84-8
   PubMed Web of Science ®Google Scholar
• Homey B, Steinhoff M, Ruzicka T, Leung DYM. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 2006;118:178-89
   PubMed Web of Science ®Google Scholar
• Ong PY, Ferdman RM, Dunaway T, et al. Down-regulation of atopic dermatitis-associated serum chemokines by wet-wrap treatment: a pilot study. Ann Allergy Asthma Immunol 2008;100:286-7
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117:411-7
   PubMed Web of Science ®Google Scholar
• Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003;23:6176-80
   PubMed Web of Science ®Google Scholar
• Takaoka A, Arai I, Sugimoto M, et al. Role of scratch-induced cutaneous prostaglandin D production on atopic-like scratching behaviour in mice. Exp Dermatol 2007;16:331-9
   PubMed Web of Science ®Google Scholar
• Takano N, Sakurai T, Ohashi Y, Kurachi M. Effects of high-affinity nerve growth factor receptor inhibitors on symptoms in the NC/Nga mouse atopic dermatitis model. Br J Dermatol 2007;156:241-6
   PubMed Web of Science ®Google Scholar
• Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 2007;127:2228-35
   PubMed Web of Science ®Google Scholar
• Tominaga M, Ogawa H, Takamori K. Decreased production of semaphorin 3A in the lesional skin of atopic dermatitis. Br J Dermatol 2008;158:842-4
   PubMed Web of Science ®Google Scholar
• Yamaguchi J, Nakamura F, Aihara M, et al. Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model. J Invest Dermatol 2008;128:2842-9
   PubMed Web of Science ®Google Scholar